Adoptive T-cell therapy (ACT) is an emerging paradigm in which T cells are genetically modified to target cancer-associated antigens and eradicate tumors. However, challenges treating epithelial cancers with ACT reflect antigen targets that are not tumor-specific, permitting immune damage to normal tissues, and preclinical testing in artificial xenogeneic models, preventing prediction of toxicities in patients. In that context, mucosa-restricted antigens expressed by cancers exploit anatomical compartmentalization which shields mucosae from systemic antitumor immunity. This shielding may be amplified with ACT platforms employing antibody-based chimeric antigen receptors (CARs), which mediate MHC-independent recognition of antigens. GUCY2C is a cancer mucosa antigen expressed on the luminal surfaces of the intestinal mucosa in mice and humans, and universally overexpressed by colorectal tumors, suggesting its unique utility as an ACT target. T cells expressing CARs directed by a GUCY2C-specific antibody fragment recognized GUCY2C, quantified by expression of activation markers and cytokines. Further, GUCY2C CAR-T cells lysed GUCY2C-expressing, but not GUCY2C-deficient, mouse colorectal cancer cells. Moreover, GUCY2C CAR-T cells reduced tumor number and morbidity and improved survival in mice harboring GUCY2C-expressing colorectal cancer metastases. GUCY2C-directed T cell efficacy reflected CAR affinity and surface expression and was achieved without immune-mediated damage to normal tissues in syngeneic mice. These observations highlight the potential for therapeutic translation of GUCY2C-directed CAR-T cells to treat metastatic tumors, without collateral autoimmunity, in patients with metastatic colorectal cancer.
Introduction
Colorectal cancer (CRC) is the fourth leading cause of cancer, and the second leading cause of cancer-related death in the United States and world. 1 While surgical excision of primary tumors can be curative, particularly at the earliest stages of disease, about 50% of patients with colorectal cancer ultimately die of distant metastases. 1 While chemo-, radio-, and targeted therapies extend survival to about 24 mo, less than 15% of patients with metastatic CRC survive beyond 5 y, 1 highlighting the unmet need for new therapeutic paradigms for this disease.
Adoptive T-cell therapy (ACT) is an emerging platform 2 to treat patients with advanced cancer employing autologous tumor-specific T cells that are expanded ex vivo and transferred back into patients. While initial approaches employed tumorinfiltrating lymphocytes (TILs) to treat melanoma, 3 genetic modification of bulk peripheral blood T cells to express antigen-specific receptors theoretically extends this approach to all cancers, with notable success in treating leukemia and neuroblastoma. [4] [5] [6] However, ACT has had limited utility against epithelial tumors, reflecting unresolved issues surrounding toxicities. Indeed, employing receptors directing genetically modified T cells to target antigens that are shared by tumors and normal tissues can produce severe autoimmune damage and patient death. 7, 8 Moreover, ACT products examined clinically have been tested in preclinical mouse models devoid of endogenous target antigen, incompletely characterizing the potential for toxicities in normal tissues. 9, 10 In that context, T cells engineered to express an affinity-enhanced TCR targeting the colorectal tumor antigen carcinoembryonic antigen (CEA), also broadly expressed by intestinal epithelial cells, produced severe colitis in patients. 8 Similarly, T cells modified to express an antibody-based chimeric antigen receptor (CAR) targeting the tumor antigen ERBB2 (Her-2) produced lethal pneumonitis in the only patient receiving this therapy, reflecting Her-2 expression in lung. 7 These considerations highlight the importance of identifying tumor-selective antigens, immune cell platforms that optimally discriminate tumor and normal tissues, and syngeneic preclinical models to define the biology, efficacy, and safety of new ACT paradigms. [11] [12] [13] Guanylyl cyclase C (GUCY2C) is a membrane-bound cyclase whose cell-surface expression is confined to the apical surfaces of intestinal epithelial cells and exhibits limited expression in extra-intestinal tissues of humans and mice. 14, 15 Of significance, GUCY2C is a cancer mucosa antigen, 16 universally overexpressed by primary and metastatic human CRCs and is ectopically expressed in esophageal and gastric cancers associated with intestinal dysplasia. 14, 15, 17, 18 Moreover, anatomical segregation of GUCY2C on the luminal surface of the intestinal epithelium [19] [20] [21] [22] limits access to systemically delivered GUCY2C-targeted molecules permitting diagnostic imaging 23 and monoclonal antibody-based therapy 24, 25 of colorectal cancer metastasis without recognition of intestinal epithelium.
Further, GUCY2C vaccines induce CD8
C T cell and antibody responses that eliminate metastatic colorectal tumors, without autoimmunity, in syngeneic mouse models [26] [27] [28] and this platform is currently being tested in humans. 29 Beyond vaccines, luminal compartmentalization of GUCY2C offers an intriguing solution to toxicities of current ACT paradigms against metastatic CRC. Moreover, a syngeneic mouse model, in which endogenous target antigen expression in normal tissue and tumors closely models humans, offers a unique opportunity to directly test CAR-T cell therapeutic efficacy and toxicity. The present study examined the ability of CAR-T cells directed to murine GUCY2C to treat established parenchymal CRC metastases without autoimmunity. This study establishes proof-of-principle for safe and effective GUCY2C CAR-T cell therapy, which can be translated to CRC patients.
Results

GUCY2C CAR-T cells
Monoclonal antibodies targeting the GUCY2C extracellular domain (GUCY2C ECD ) generated from hybridomas (MS7, MS20, Figure 1 . Characterization of GUCY2C-specific antibodies and CAR constructs. (A) Monoclonal antibodies generated against GUCY2C (MS7, MS20, and MS24) were assessed by ELISA for specific binding to GUCY2C ECD or negative control bovine serum albumin (BSA) plated at 1 mg/mL, ÃÃÃÃ p < 0.0001 (Two-way ANOVA of GUCY2C vs. BSA -binding for each mAb). (B) Wild-type (Gucy2c
) mouse colon sections were stained with GUCY2C-specific monoclonal antibodies (green), demonstrating specificity of antibodies for GUCY2C in the intestine. DAPI (blue). Representative of three sections each. (C) Flow cytometry analysis was performed on GUCY2C-deficient (CT26) and GUCY2C-expressing (CT26.GUCY2C) CT26 mouse colorectal cancer cells stained with GUCY2C mAbs. Results are representative of two experiments. (D) A third generation CAR construct was synthesized containing the BiP signal sequence, scFv, the CD8a hinge region, the transmembrane and intracellular domain of CD28, the intracellular domain of 4-1BB (CD137) and the intracellular domain of CD3z. The CAR construct was inserted into the MSCV retroviral plasmid pMIG upstream of an IRES-GFP marker. (D) Murine CD8
C T cells transduced with a retrovirus containing a Control CAR or CARs derived from GUCY2C antibodies (MS7 and MS24) were labeled with varying concentrations of purified 6xHis-GUCY2C ECD (0-10 mM) detected with a5xHis-Alexa-647 conjugate. Flow plots ( and MS24) recognized purified GUYC2C (Fig. 1A) , GUCY2C in the colon (Fig. 1B) , and small intestine (Fig. S1 ) of Gucy2c C/C , but not Gucy2c ¡/¡ , mice; and GUCY2C-expressing, but not GUCY2C-deficient, CT26 murine colorectal cancer cells (Fig. 1C) . Heavy and light chain variable region sequences from each of the GUCY2C-specific hybridomas were used to generate third-generation CARs (Fig. 1D ), which were inserted into a retroviral construct used to infect T cells with~65% transduction efficiencies (Fig. S2 ). GUCY2C-binding avidity was quantified by incubating CAR-T cells with increasing concentrations of purified 6xHis-tagged GUCY2C ECD , followed by detection with labeled a6xHis antibody and assessment by flow cytometry (Fig. 1D and Fig. S3 ). GUCY2C binding was detected with constructs derived from the MS7 and MS24, but not MS20, antibodies. CARs derived from MS24 exhibited~22-fold greater avidity (K av 44.3 nM vs. 994.2 nM; p D 0.0567) and~5-fold greater surface expression (B max 741.5 vs. 144.2; p < 0.0001) compared to MS7-derived CARs (Fig. 1D) , similar to the higher avidity of MS24 monoclonal antibody in comparison to MS7 (Fig. S4) .
GUCY2C CARs mediate antigen-specific activation of T cells MS7 and MS24, but not MS20 or control, CAR-T cells upregulated CD25 and CD69 30 when stimulated with immobilized GUCY2C ECD , but not BSA (Fig. 2) . All T cells produced comparable levels of CD25 and CD69 when stimulated with PMA and ionomycin, confirming that transduction with different CARs did not impact T cell activation. MS24 CAR mediated greater activation than MS7 CAR (Fig. 2) , consistent with its 22-fold higher avidity (Fig. 1D ). MS20 CAR was excluded from further consideration reflecting its inability to bind GUCY2-C ECD (Fig. S3) or mediate GUCY2C-dependent T cell activation (Fig. 2) . MS7 and MS24, but not control, CAR-T cells produced effector cytokines IFNg, TNFa, and MIP-1a when stimulated with immobilized GUCY2C ECD , but not BSA (Fig. 3) . Importantly, MS24 CAR-T cells exhibited greater polyfunctionality than MS7 CAR-T cells (Fig. 3B) characterized by a reduction in cells producing no cytokines (p < 0.0001, Twoway ANOVA) and an increase in cells producing two or three cytokines (p < 0.05 and p < 0.0001, respectively, Two-way ANOVA) following GUCY2C stimulation. Similarly, MS7 and MS24, but not control, CAR-T cells lysed GUCY2C-expressing, but not GUCY2C-deficient, CT26 mouse colon cancer cells (Fig. 4) . As expected, MS24 CAR T cells lysed GUCY2C-expressing CT26 cells more rapidly than MS7 CAR-T cells (half-maximal lysis at 54 min vs. 200 min; p < 0.05; Figs. 4B and D) consistent with its higher avidity (Fig. 1D ).
GUCY2C CAR-T cells oppose metastatic colorectal cancer
Mice received CT26.GUCY2C cells by tail vein to induce lung metastases, 31 followed 3 d later by 5 Gy total body irradiation (TBI) and 1 £ 10 7 T cells. 32 A non-myeloablative dose of 5 Gy TBI was administered prior to T cell transfer to enhance the efficacy of adoptive T cell therapy by reducing sinks for the homeostatic cytokines IL-7 and IL-15. 33, 34 The number of tumors in lungs of mice treated with GUCY2C CAR-T cells was significantly reduced compared to mice treated with control CAR-T cells (Figs. 5A and B). Moreover, GUCY2C CAR-T cell-treated mice exhibited reduced morbidity, quantified by cachexia (Fig. 5C ), and improved survival (Fig. 5D ). As expected, morbidity ( Fig. 5C ) and survival ( Fig. 5D ) were significantly better with MS24, compared to MS7, CAR-T cells.
GUCY2C CAR-T cells do not induce autoimmunity
MS24 CAR-T cells produce the greatest GUCY2C-dependent T cell activation (Fig. 2 ), cytokine production ( Fig. 3) , cytolysis (Fig. 4) , and antitumor efficacy ( tissues by histopathology ( Fig. 6D ) and exhibited normal organ and metabolic functions quantified by serum chemistries (Fig. S5 ).
Discussion
This study provides the first proof-of-principle for GUCY2C CAR-T cells to treat parenchymal colorectal cancer metastases without autoimmunity in a syngeneic mouse model. Immunologic competence of GUCY2C CARs was reflected by the ability of GUCY2C, but not control, CAR-T cells to engage GUCY2C and induce T cell activation ( Fig. 2 ) and effector function (Figs. 3 and 4). Immunologic competence was associated with the ability of GUCY2C, but not control, CAR-T cells to induce GUCY2C-dependent cytokine production ( Fig. 3 ) and in vitro colorectal cancer cell cytolysis (Fig. 4) . Further, GUCY2C, but not control, CAR-T cells reduced disease burden, improved morbidity, and produced durable eradication of disease in a mouse model of GUCY2C-expressing colorectal cancer metastases in lung (Fig. 5 ). Moreover, therapeutic efficacy was achieved without immune-mediated tissue damage, in small and large intestine or other extra-intestinal tissues ( Fig. 6 and Fig. S5 ). Importantly, the superior therapeutic efficacy and safety of GUCY2C CAR-T cells was achieved in a syngeneic mouse model in which GUCY2C was endogenously expressed in normal tissues in a pattern recapitulating that in humans, colorectal tumors expressed an identical antigen, and T cells were directed by CAR receptors to that endogenous antigen. Taken together, these observations suggest that GUCY2C-targeted CAR-T cells could eradicate tumors without autoimmunity in patients with metastatic colorectal cancer.
One key limitation to translating ACT to epithelial tumors generally, and colorectal cancer specifically, is the paucity of tumor-specific antigens to which immune cells can be targeted. In that context, targeting tumor-associated self-antigens risks development of "on-target, off-tumor" toxicities and therapylimiting autoimmunity. 35, 36 CEA is an antigen that is normally expressed by intestinal and lung epithelial cells, and overexpressed by colorectal tumors. While T cells directed to CEA exhibit antitumor efficacy, their administration to patients produced treatment-limiting colitis. 8 Similarly, Her-2 also is expressed by normal epithelial cells and overexpressed by colorectal tumors, and T cells targeting this antigen produced lethal immune-mediated damage to normal lung in a patient. 7 In contrast, GUCY2C may be uniquely suited to direct immune cells to colorectal metastases without autoimmunity due to its sequestered expression on apical surfaces of intestinal epithelia. [19] [20] [21] Thus, GUCY2C-targeted CAR T cells eradicated GUCY2C-expressing pulmonary metastases without immune damage to intestinal epithelia (Fig. 6 ). GUCY2C-targeted imaging agents, 23 immunotoxins, 25 and vaccines [26] [27] [28] recognize GUCY2C-expressing metastatic colorectal tumors, but not normal intestinal epithelia. Indeed, universal overexpression of GUCY2C on the surface of metastatic tumors, 17, 18, 37 but its absence on basolateral membranes of epithelial cells [19] [20] [21] may shield normal intestine from systemic GUCY2C-targeted therapies. In that context, T cells directed to CEA, whose epitopes are presented by MHC in apical and basolateral membranes of intestinal cells, were characterized by antigen-dependent intestinal accumulation and colitis in mouse models 38, 39 and patients. 8 In contrast, mice treated with GUCY2C CAR-T cells were free of intestinal accumulation and toxicity (Fig. 6) , underscoring the importance of GUCY2C sequestration in apical membranes to prevent CAR-T cell recognition, accumulation, and toxicity. Beyond intestinal mucosa, GUCY2C expression recently was described in neurons of hypothalamus, an immunologically privileged compartment, where it regulates satiety and appetite. 40 GUCY2C levels in hypothalamus are 10-fold lower than those in intestine. 40 In that context, sufficient quantities of antigen on the surface of cellular targets are necessary to induce CAR T cell activation.
41 GUCY2C-targeted CAR T cells or immunotoxins 25 did not damage hypothalamic neurons, supporting the suggestion that they are sequestered from systemically targeted agents and/or express GUCY2C at levels below detection by our monoclonal antibodies. Taken together, the narrow pattern of expression in normal tissues, expression in compartments which are anatomically shielded or immunologically privileged, and universal overexpression by metastatic tumors suggest that GUCY2C is uniquely qualified as an antigenic target to which T cells can be directed to treat metastatic CRC without autoimmunity.
Beyond selectivity of expression in normal tissues and tumors, aligning ACT platforms with patterns of antigen expression within tissues can minimize treatment-limiting adverse events. For example, CEA is expressed in apical membranes of intestinal epithelial cells, and is presumably inaccessible to targeted CAR-T cells which recognize native antigen in an MHC-independent fashion. 5, 42 Indeed, CAR-T cells directed to human CEA did not produce colitis in a transgenic mouse model recapitulating human CEA expression. 38 However, T cells directed by recombinant TCRs recognize peptide antigens in the context of MHC. 43 In turn, MHC-peptide complexes can be presented on basolateral membranes of intestinal epithelial cells 44 or cross-presented by antigen-presenting cells in tissues or lymphoid organs, 45 abrogating the anatomical shielding of natively-expressed apical membrane proteins.
Indeed, T cells directed by CEA-specific TCRs produce severe colitis in mice and humans. 8, 39 Thus, aligning GUCY2C as an apical target antigen, with CAR platforms to direct MHC-independent elimination of tumor cells, should maximize the benefit of luminal sequestration in normal tissues, optimizing therapeutic discrimination between tumors and intestine, as observed here.
Utilization of receptors targeting self-antigens to direct engineered T cells, and the associated incomplete discrimination of normal tissues and tumors, creates an imperative to define their safety and therapeutic efficacy in preclinical models that emulate the expression of target antigens in patients. However, the translation of ACT to patient-based trials has been based largely on the safety and efficacy of these paradigms in artificial human tumor xenograft systems. In some cases, the target antigen was not expressed in normal tissues, making it impossible to assess safety. 9, 10 In other cases, transgenic models attempt to emulate the expression of the human antigen in normal tissues in patients. For example, CEA CAR-T cells exhibited antitumor efficacy without immune-mediated damage to normal tissues in CEA-transgenic mice. 38 Nevertheless, safety profiles achieved with artificial xenogeneic preclinical models must be viewed with some caution. Indeed, in other CEA transgenic mouse models, antitumor efficacy of CEA-specific T cells was associated with severe immune-mediated colitis. 39 More significantly, a recent clinical trial of CEA-specific T cells induced severe autoimmune colitis, which represented dose-limiting toxicity and required discontinuation of therapy. 8 Further, human Her-2 transgenic mice treated with large doses of CAR-T cells derived from the human Her-2 specific antibody 4D5, 46 but not the FRP5 antibody, 47 caused death within 4 d of treatment. This effect was not achieved with lower doses of 4D5 CAR-T cells; however, a colorectal cancer patient treated with 4D5 CAR-T cells also died following treatment, with potential evidence of antigen-specific toxicities in lung epithelium. 7 These conflicting reports highlight the challenges of extrapolating safety profiles of ACT defined in transgenic mouse models, particularly if antigen expression levels do not mimic those in humans.
These considerations underscore the importance of establishing safety and efficacy profiles of ACT in syngeneic models in which engineered T cells are directed by receptors targeting antigens endogenously expressed in normal tissues. 11 Indeed, CAR-T cells targeting murine CD19 eliminate B cell leukemia in mice with concomitant loss of normal B cells, 12, 48 recapitulating observations in clinical trials. 4, 5 Separately CAR-T cells targeting stromal FAP and VEGFR-2 also produce significant toxicities in mice. 13, 49 CAR-T cells targeting FAP cause lethal bone marrow toxicity in mice reflecting FAP expression on multipotent bone marrow stem cells. 13 Further, VEGFR-2 CAR-T cells caused toxicity only in tumor-bearing mice, mediated by CAR-expressing CD4 C , but not CD8 C , T cells. 49 In the present study, we demonstrated that CAR-T cells directed to murine GUCY2C eradicated GUCY2C-expressing colorectal tumors metastatic to lungs, without inducing autoimmunity in intestine or other normal tissues in mice endogenously expressing the target antigen. However, CAR-T cell toxicity typically reflects acute cytokine production and tissue damage, 50 and the long-term toxicity of GUCY2C CAR-T cell therapy could not be evaluated here. In that context, GUCY2C CAR-T cell persistence was limited (Fig. S6) , reflecting their production in the presence of IL-2. Recent analysis of the impact of cytokine milieu during CAR-T cell production and in vivo following their administration, suggest that alternative cytokine combinations may produce CAR-T cells with enhanced persistence and antitumor efficacy. 51 Indeed, CAR-T cell production in the presence of IL-2 produced highly differentiated CAR-T cells with the least in vivo persistence and antitumor efficacy, compared to IL-7, IL-15, IL-18, IL-21, or no cytokines. Thus, as cell production methods continue to be refined, toxicity will be re-evaluated to determine if improving GUCY2C CAR-T cell persistence and antitumor efficacy concomitantly increases their associated toxicity targeting antigen-expressing tissues.
Taken together, these observations provide proof-of-principle in a uniquely relevant preclinical syngeneic model that GUCY2C-targeted CAR-T cells could be clinically effective, without inducing autoimmune tissue damage, in patients with metastatic colorectal cancer. This paradigm leverages the unique structural compartmentalization of GUCY2C endogenously expressed in normal tissues, [19] [20] [21] [22] and the universal overexpression of this antigen by metastatic colorectal tumors. 17, 18, 37 It offers an immunotherapeutic strategy to treat bulky metastatic disease, which is complementary to GUCY2C vaccines as secondary prevention of metastatic disease in CRC patients at risk. [26] [27] [28] The significance of these observations can best be appreciated by considering that metastatic CRC is nearly always fatal, without curative therapeutic options. 1 Moreover, beyond CRC, GUCY2C-targeted ACT offers a unique therapeutic option to treat metastases in patients with gastric, esophageal, and pancreatic cancers which also are universally fatal and which ectopically express GUCY2C after transformation. 17 Translation of these observations into patients will require the development of monoclonal antibodies to human GUCY2C, their incorporation into CAR constructs, and testing of their therapeutic efficacy in mice harboring human colorectal cancer metastases.
Materials and methods
Mouse GUCY2C monoclonal antibodies
The monoclonal antibodies (MS7, MS20, and MS24) recognize mouse GUCY2C, 40 CT26.GUCY2C cells, 28 and 6xHis-tagged GUCY2C ECD protein. 28 GUCY2C-specific antibodies were tested by ELISA as previously described.
28 FACS: CT26 tumor cells were stained with 10 mg/mL GUCY2C-specific antibody follow by detection with anti-mouse conjugated to Alexa-488 and assessed for surface expression using the BD LSR II flow cytometer. Immunohistochemistry: intestinal tissues from wild-type and Gucy2c ¡/¡ BALB/c mice were fixed in formalin and paraffin embedded. Tissue sections were stained with 5 mg/mL GUCY2C-specific monoclonal antibody followed by detection with antimouse antibody conjugated to Alexa-488 and mounted in ProLong Gold Antifade Reagent with DAPI (Life Technologies). Images were captured using the EVOS FL Auto Cell imaging system.
CAR construction
A third generation codon-optimized CAR was synthesized containing the BiP (GRP-78) signal peptide, and scFv from the murine 4D5 monoclonal antibody specific for human ERBB2, 52 CD8a hinge region, CD28 transmembrane and intracellular domains, and 4-1BB (CD137) and CD3z intracellular domains in the pMA entry plasmid (GeneArt). CARs derived from the 4D5 antibody served as the negative control CAR in all experiments performed. V L and V H variable regions were cloned from MS7, MS20, and MS24 hybridomas by RT-PCR using degenerate primers and linked with a glycine-serine linker (G 4 S) 4 by overlap extension PCR. Resulting GUCY2C-specific scFv constructs were subcloned into the synthesized CAR construct, replacing 4D5.
Retrovirus production and T cell transduction
CARs were subcloned into the pMSCV-IRES-GFP (pMIG) retroviral vector using XhoI and EcoRI restriction sites. The Phoenix-Eco retroviral packaging cell line (Gary Nolan, Stanford University) was transfected with CAR-pMIG vectors and the pCL-Eco retroviral packaging vector (Imgenex) using the Calcium Phosphate Profection R Mammalian Transfection System (Promega). Retrovirus-containing supernatants were collected 48 h later, filtered through 0.45 mM filters, and aliquots were frozen at ¡80
C. Murine CD8 C T cells were purified from BALB/c splenocytes using the CD8aC T cell Isolation Kit II (Miltenyi Biotec) and subsequently stimulated with aCD3/aCD28-coated beads (T Cell Activation/Expansion Kit, Miltenyi Biotec) at a 1:1 bead:cell ratio at 1 £ 10 6 cells/mL in cRPMI (RMPI C 10% FBS, 10 mM HEPES, 0.05 mM 2-mercaptoethanol) with 100 U/mL recombinant human IL-2 (NCI Repository). The day following stimulation, 1 = 2 of the culture media was carefully replaced with an equal volume of thawed retroviral supernatant in the presence of polybrene (Millipore). Spinoculation was performed at room temperature for 90 min at 2,500 rpm followed by incubation at 37 C for 2.5 h at which point cells were pelleted and resuspended in fresh media containing IL-2. T cells were expanded for 7-10 d by daily dilution to 1 £ 10 6 cells/mL with fresh cRPMI and IL-2 at which point they were used for functional assays. All cell counts employed a Muse Cell Analyzer and Count and Viability Assay (Millipore). Serum lots were not pretested for performance.
CAR surface detection
CAR-transduced T cells were stained with the Live/Dead Fixable Aqua Dead Cell Stain kit (Invitrogen), labeled with varying concentrations of 6xHis-tagged GUCY2C ECD for 1 h, stained with the a5xHis Alexa-647 conjugate (Qiagen) and aCD8b-PE (clone H35.17.2, BD Biosciences) for 1 h, fixed with 2% PFA and analyzed using the BD LSR II flow cytometer and FlowJo software (Tree Star). GUCY2C binding was quantified by determining the mean fluorescence intensity of Alexa-647 on live CD8
C GFP C cells. Non-linear regression analysis (GraphPad Prism v6) was used to determine the K av and B max of GUCY2C-CAR binding.
Surface activation marker and intracellular cytokine staining
CAR-transduced T cells were stimulated for 6 h with antigen coated on tissue culture plates at 1 mg/mL in PBS overnight at 4 C, or with Cell Stimulation Cocktail (PMA/Ionomycin, eBioscience). Incubation included the Protein Transport Inhibitor Cocktail (eBioscience) when assessing intracellular cytokines. Cells were stained with Live/Dead fixable Aqua Dead Cell stain kit (Invitrogen) and subsequently stained for surface markers using the following antibodies: aCD8a-PerCP-Cy5.5 (clone 53.6-7) and aCD69-PE (clone H1.2F3) from BD Biosciences and aCD25-PE (clone PC61.5, eBioscience). Intracellular cytokine staining was performed using the BD Cytofix/Cytoperm Kit (BD Biosciences) and staining with the following antibodies: aGFP-Alexa-488 (Invitrogen), aIFNg-APC-Cy7 (XMG1.2) and aTNFa-PE-Cy7 (MP6-XT22) from BD Biosciences, and aMIP1a-PE (clone 39624, R&D Systems). Cells were fixed in 2% PFA and analyzed on a BD LSR II flow cytometer. Analyses were performed using FlowJo software (Tree Star).
Real time cell-mediated cytotoxicity assay
The xCELLigence system (Acea Biosciences Inc.) was utilized for assessment of T cell-mediated cytotoxicity. 53 Briefly 1 £ 10 4 CT26 or CT26.GUCY2C targets were plated in 150 mL of DMEM 10% FBS in each well of an E-Plate 16 and grown overnight, quantifying electrical impedance every 15 min, using the RTCA DP Analyzer system (Acea Biosciences Inc.). Approximately 24 h later, 50 mL of CAR-T cells was added at an effector-to-target (E:T) ratio of 5:1 or 50 mL of media or 10% Triton-X 100 were added as negative and positive controls, respectively. Cell-mediated killing was quantified over the next 16 h reading electrical impedance every 15 min. Percent-specific lysis values were calculated using GraphPad Prism Software v6 for each replicate at each time point, using impedance values following the addition of media and Triton for normalization (0% and 100% specific lysis, respectively).
Metastatic tumor model
BALB/c mice were obtained from the NCI Animal Production Program (Frederick, MD). Animal protocols were approved by the Thomas Jefferson University Institutional Animal Care and Use Committee. Male BALB/c mice were challenged with 5 £ 10 5 CT26.GUCY2C cells by tail vein injection to establish lung metastases. On day 3 following tumor injections, mice received a non-myeloablative dose of 5 Gy total body irradiation in a PanTak, 310 kVe x-ray machine. Mice received~1 £ 10 7 fresh CAR-T cells in 100 mL PBS following irradiation by tail vein injection. Mice were followed for cachexia (twice weekly body weights) and survival, or sacrificed at day 23 after tumor cell injection and lungs were stained with India ink and fixed in Fekete's solution for tumor enumeration. 28 
Toxicity
For T cell accumulation, 1 £ 10 7 MS24 CAR-T cells were administered to BALB/c mice with CT26.GUCY2C lung metastases established 14 d earlier following 5 Gy TBI. Lungs, spleens, and intestines were collected 2 d later, and tissue sections were stained with anti-GUCY2C (MS20) and anti-GFP antibodies and counterstained with DAPI. GFPC MS24 CAR-T cells were quantified in remnant follicles in spleen, tumor metastases in lungs, and Peyer's patches in intestines and normalized to area (mm 2 ). A cell was considered to be GFPC if fluorescence intensity was above the background level (set using corresponding GFP-negative control tissues) associated with a DAPI-stained nucleus in the same plane. For histopathology, tissues and serum were collected from mice 6 d after treatment with PBS, 5 Gy TBI, or 5 Gy TBI and CAR-T cells. Tissues were fixed in formalin and embedded in paraffin. Sections were stained with hematoxylin and eosin and scored for toxicity by a blinded pathologist (P.L.). Scoring criteria are listed in Table S1 . Serum chemistries were commercially determined (Charles River Laboratories). 
Statistical analyses
Statistical analyses were conducted using GraphPad Prism Software v6. All results are representative of at least three experiments unless otherwise indicated.
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